Moscow, Nov. 25 -- Russia's Sputnik V vaccine has been found to be more than 95 per cent effective against Covid-19 in the second interim analysis of Phase 3 clinical trial data, its developers said on Tuesday.

The analysis was based on data from volunteers obtained 42 days after the first dose - which corresponds with 21 days after the second dose, Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Health Ministry and Russian Direct Investment Fund (RDIF), said.

And based on data obtained 28 days after administering the first dose - seven days after the second dose, the efficacy of the Sputnik V vaccine was found to be 91.4 per cent.

"The data demonstrating high efficacy of the Sputnik V vaccine gives u...